Lamivudine/tenofovir

Lamivudine/tenofovir is a combination antiretroviral medication used in the treatment of HIV/AIDS. It is a fixed-dose combination of two antiretroviral drugs: lamivudine and tenofovir disoproxil. This combination is used to help control HIV infection, improve the immune system, and reduce the risk of developing AIDS-related illnesses.
Medical Uses[edit]
Lamivudine/tenofovir is primarily used in the treatment of HIV infection. It is often prescribed as part of a combination therapy with other antiretroviral agents. The combination works by inhibiting the action of the reverse transcriptase enzyme, which is crucial for the replication of the HIV virus. By doing so, it helps to lower the viral load in the body and increase the number of CD4+ T cells, thereby improving the immune function.
Mechanism of Action[edit]
Lamivudine and tenofovir are both nucleoside reverse transcriptase inhibitors (NRTIs). They work by mimicking the natural nucleosides that the virus uses to synthesize DNA. When the virus incorporates these drugs into its DNA chain, it results in premature termination of the DNA strand, thereby inhibiting viral replication.
Lamivudine[edit]
Lamivudine is a synthetic nucleoside analogue that is phosphorylated intracellularly to its active form, lamivudine triphosphate. This active form competes with the natural substrate, deoxycytidine triphosphate, for incorporation into viral DNA.
Tenofovir[edit]
Tenofovir disoproxil is a prodrug of tenofovir, which is an analogue of adenosine 5'-monophosphate. Once inside the cell, it is converted to tenofovir diphosphate, which inhibits the activity of HIV-1 reverse transcriptase by competing with the natural substrate, deoxyadenosine 5'-triphosphate.
Side Effects[edit]
Common side effects of lamivudine/tenofovir include nausea, diarrhea, headache, fatigue, and dizziness. More serious side effects can include lactic acidosis, liver problems, and kidney issues. Patients are advised to have regular monitoring of liver and kidney function while on this medication.
Contraindications[edit]
Lamivudine/tenofovir is contraindicated in patients with known hypersensitivity to either component of the combination. Caution is advised in patients with pre-existing liver or kidney disease.
Related Pages[edit]
Sponsored Health Resource

W8MD Weight Loss, Sleep & MedSpa
Looking for physician-supervised weight loss, semaglutide, tirzepatide, or GLP-1 receptor agonist options? W8MD helps eligible patients in New York City, Brooklyn, New Jersey, Connecticut, Pennsylvania, Delaware, and greater Philadelphia with medical weight loss, sleep medicine, and long-term maintenance support.
GLP-1 specials: Affordable GLP-1 injections NYC and Philadelphia starting from $29.99/week and up for semaglutide with insurance accepted for qualifying visits, and $45/week and up for tirzepatide with insurance accepted for qualifying visits. Self-pay options start from $59.99/week and up for semaglutide and $69.99/week and up for tirzepatide.
- Medical weight loss NYC
- Affordable GLP-1 injections NYC
- Budget GLP-1 weight loss shots Philadelphia
- New Jersey medical weight loss
- NYC medical weight loss blog
- Philadelphia weight loss blog
- Sleep medicine and sleep apnea services
- W8MD MedSpa and wellness
Book a W8MD appointment · View GLP-1 specials
Paid promotional message. Eligibility, pricing, insurance coverage, medication availability, and results vary. Medical evaluation required.
Medical Disclaimer: WikiMD is for informational purposes only and is not a substitute for professional medical advice. Content may be inaccurate or outdated and should not be used for diagnosis or treatment. Always consult your healthcare provider for medical decisions. Verify information with trusted sources such as CDC.gov and NIH.gov. By using this site, you agree that WikiMD is not liable for any outcomes related to its content. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Translate page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian